S. 164 117th Congress
Advancing Education on Biosimilars Act of 2021
- Became Public Law 117-8
- Health
- Sponsor: Sen. Hassan, Margaret Wood [D-NH]
- Congress.gov ↗
Latest action, Apr 23, 2021: Became Public Law No: 117-8.
How the House voted: On Motion to Suspend the Rules and Pass
Apr 14, 2021 · Passed · 412–8 (it needed 2/3)
- Yea (412)
- Nay (8)
- Didn't vote (9)
- Letters: party (D, R, I)
By party
- Democrat
- Republican
- Independent
1 cosponsor
Sponsored by Sen. Hassan, Margaret Wood [D-NH] (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
0 D · 1 R
Referred to: Senate: Health, Education, Labor, and Pensions Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
COHERUS BIOSCIENCES
RED+BLUE STRATEGIES
8 reports
8 reports
8 reports
7 reports
6 reports
3 reports
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
COVINGTON & BURLING LLP
2 reports
THE BIOSIMILARS FORUM
THORN RUN PARTNERS
2 reports
1 report
All 11 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | House |
|---|---|---|---|---|---|---|
| COHERUS BIOSCIENCES | RED+BLUE STRATEGIES | 8 | $0 | Q1 2021 | Q3 2022 | yes |
| GSK (FKA GLAXOSMITHKLINE INC.) | 8 | $9.8M | Q1 2021 | Q3 2022 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 8 | $57.9M | Q1 2021 | Q3 2022 | yes | |
| TEVA PHARMACEUTICALS USA INC | 8 | $7.8M | Q1 2021 | Q3 2022 | yes | |
| NATIONAL MULTIPLE SCLEROSIS SOCIETY | 7 | $357K | Q4 2021 | Q3 2022 | yes | |
| NOVARTIS | 6 | $9.7M | Q1 2021 | Q2 2022 | yes | |
| AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 3 | $1.2M | Q1 2021 | Q3 2021 | yes | |
| COHERUS BIOSCIENCES, INC. | 3 | $330K | Q1 2021 | Q3 2021 | yes | |
| PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC | COVINGTON & BURLING LLP | 2 | $0 | Q1 2021 | Q2 2021 | yes |
| THE BIOSIMILARS FORUM | THORN RUN PARTNERS | 2 | $180K | Q1 2021 | Q2 2021 | yes |
| PRIME THERAPEUTICS | 1 | $90K | Q2 2021 | Q2 2021 | yes |